ORIONS Money Stocks

[Covid19freak]

(ORTX) MC $58 m..Cash $170 m...company has already an approved drug in europe and they expect to submit BLA for US approval by year end . company trading massive under cash and has strong institutional ownership .this one could double or triple quickly on good news .


https://finance.yahoo.com/news/orchard-therapeutics-reports-second-quarter-110000893.html

Key Upcoming Clinical and Research Milestones ;

OTL-200 for MLD (U.S.): Conduct a pre-Biologics License Application (BLA) meeting with U.S. Food and Drug Administration (FDA) in the second half of 2022 in advance of a BLA submission timeline of late 2022 to early 2023.

OTL-203 for MPS-IH: Initiate a global registrational study in 2023.

OTL-201 for MPS-IIIA: Report clinical data, including early clinical outcomes of cognitive function, from the proof-of-concept (POC) trial by year end 2022.